PortfoliosLab logoPortfoliosLab logo
SDGR vs. VKTX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

SDGR vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Schrodinger, Inc. (SDGR) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

SDGR vs. VKTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
SDGR
Schrodinger, Inc.
-35.40%-7.31%-46.12%91.55%-46.34%-56.01%176.47%
VKTX
Viking Therapeutics, Inc.
-6.31%-12.57%116.23%97.98%104.35%-18.29%-15.84%

Fundamentals

Market Cap

SDGR:

$848.27M

VKTX:

$3.76B

EPS

SDGR:

-$1.41

VKTX:

-$3.19

PB Ratio

SDGR:

2.33

VKTX:

5.88

Total Revenue (TTM)

SDGR:

$255.87M

VKTX:

$0.00

Gross Profit (TTM)

SDGR:

$142.61M

VKTX:

-$208.00K

EBITDA (TTM)

SDGR:

-$85.73M

VKTX:

-$393.01M

Returns By Period

In the year-to-date period, SDGR achieves a -35.40% return, which is significantly lower than VKTX's -6.31% return.


SDGR

1D
1.67%
1M
-4.94%
YTD
-35.40%
6M
-45.54%
1Y
-38.69%
3Y*
-24.02%
5Y*
-31.84%
10Y*

VKTX

1D
1.29%
1M
-1.14%
YTD
-6.31%
6M
20.42%
1Y
37.85%
3Y*
25.56%
5Y*
39.32%
10Y*
36.57%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SDGR vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SDGR
SDGR Risk / Return Rank: 1414
Overall Rank
SDGR Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
SDGR Sortino Ratio Rank: 1414
Sortino Ratio Rank
SDGR Omega Ratio Rank: 1515
Omega Ratio Rank
SDGR Calmar Ratio Rank: 1616
Calmar Ratio Rank
SDGR Martin Ratio Rank: 1515
Martin Ratio Rank

VKTX
VKTX Risk / Return Rank: 5959
Overall Rank
VKTX Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
VKTX Sortino Ratio Rank: 5858
Sortino Ratio Rank
VKTX Omega Ratio Rank: 6262
Omega Ratio Rank
VKTX Calmar Ratio Rank: 5959
Calmar Ratio Rank
VKTX Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SDGR vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Schrodinger, Inc. (SDGR) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SDGRVKTXDifference

Sharpe ratio

Return per unit of total volatility

-0.65

0.48

-1.13

Sortino ratio

Return per unit of downside risk

-0.80

1.14

-1.94

Omega ratio

Gain probability vs. loss probability

0.91

1.17

-0.27

Calmar ratio

Return relative to maximum drawdown

-0.71

0.81

-1.52

Martin ratio

Return relative to average drawdown

-1.30

1.79

-3.09

SDGR vs. VKTX - Sharpe Ratio Comparison

The current SDGR Sharpe Ratio is -0.65, which is lower than the VKTX Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of SDGR and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


SDGRVKTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.65

0.48

-1.13

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.51

0.39

-0.90

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.20

0.12

-0.32

Correlation

The correlation between SDGR and VKTX is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

SDGR vs. VKTX - Dividend Comparison

Neither SDGR nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SDGR vs. VKTX - Drawdown Comparison

The maximum SDGR drawdown since its inception was -90.21%, roughly equal to the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for SDGR and VKTX.


Loading graphics...

Drawdown Indicators


SDGRVKTXDifference

Max Drawdown

Largest peak-to-trough decline

-90.21%

-90.41%

+0.20%

Max Drawdown (1Y)

Largest decline over 1 year

-58.52%

-45.14%

-13.38%

Max Drawdown (5Y)

Largest decline over 5 years

-85.95%

-78.86%

-7.09%

Max Drawdown (10Y)

Largest decline over 10 years

-89.26%

Current Drawdown

Current decline from peak

-89.79%

-65.12%

-24.67%

Average Drawdown

Average peak-to-trough decline

-63.33%

-59.92%

-3.41%

Ulcer Index

Depth and duration of drawdowns from previous peaks

32.00%

20.36%

+11.64%

Volatility

SDGR vs. VKTX - Volatility Comparison

The current volatility for Schrodinger, Inc. (SDGR) is 11.70%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 17.70%. This indicates that SDGR experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


SDGRVKTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.70%

17.70%

-6.00%

Volatility (6M)

Calculated over the trailing 6-month period

39.28%

45.64%

-6.36%

Volatility (1Y)

Calculated over the trailing 1-year period

59.93%

78.45%

-18.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

62.95%

101.67%

-38.72%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

70.28%

98.98%

-28.70%

Financials

SDGR vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Schrodinger, Inc. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
87.24M
0
(SDGR) Total Revenue
(VKTX) Total Revenue
Values in USD except per share items